• Ae-Nim Pae
  • Chief
  • Korea Institute of Science and Technology

Curriculum Vitae

Education

Ph.D. (1997) Department of Chemistry, Korea University

Professional Experience

2015.12-present: Head, Convergence Research Center for Dementia (DTC), KIST
2009.12-2015.12: Head, Center for Neuro-Medicine, KIST
2005.12-present: Principal Researcher, KIST
2004.8-2004.11: University of Illinois at Chicago (Prof. Pavel Petukhov)
1999.9-2000.8 : Postdoc; University of Illinois at Urbana-Champaign (Prof. Scott E. Denmark)
1997.3 -2005.2: Senior Researcher, KIST
1988.3 -1997.2: Researcher, KIST

Research Interests

Discovery of therapeutics for Alzheimer's Disease, Multiples sclerosis, neuropathic pain
Chemoinformatics based drug design, Virtual screening

Honors & Awards

2004. 4. Prime Minister Award
2013. 4. Presidential Award

Publications

1.Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease, European journal of medicinal chemistry, 2017, 125, 1172-1192,
2.Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in A beta-induced mitochondrial dysfunction, Journal of computer-aided molecular design, 2017, 31(10), 929-941
3. Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy, J. Med. Chem, 2013, 56(22), 9008

Abstract

How to Overcome the Alzheimer’s Disease: New therapeutic Strategy

Alzheimer's disease (AD) is a late-onset, progressive, age-dependent neurodegenerative disorder, characterized clinically by the impairment of cognitive functions and changes in behavior and personality. The growing population of aging leads to an increase in the number of individuals at the risk of AD. Amyloid β peptide (extracellular neuritic plaque) and tau protein (intracellular neurofibrillary tangle) are regarded as the two major pathological features. For many years, several therapeutic approaches have been tried in clinical study for AD; however, none of them can provide long term efficacy. Tau is a microtubule-associated protein that stabilize neuronal microtubule. Neurofibrillary tangles, composed of hyperphosphorylated tau fibrils. The neurofibrillary tangle load correlates strongly with clinical progression of the disease. Although tauopathy has been extensively studied as a key hypothesis in AD, there are no clinical drugs to give the noticeable improvement. Therefore, we have studied on discovery of novel tau-targeted therapeutic drug candidates for the treatment of AD, especially, tau aggregation inhibitors. We performed high-contents screening based on Tau Bi-FC in vitro assay with in-house and commercial libraries and identified novel scaffolds that exhibited excellent tau aggregation inhibitory activities and less toxic than the methylene blue which is a well-known tau aggregation inhibitor in clinical study. Currently, a variety of derivatives were synthesized through a structure-activity relationship study and the optimization of novel tau aggregation inhibitors to improve potency, physicochemical properties and in vivo efficacy is now in progress.